Cytek Biosciences Reports Loss in Q2 2025 Amid Stock Decline and Vanguard Stake Reduction
Cytek Biosciences reported a loss in the second quarter of 2025, with earnings per share matching estimates at -$0, and its stock price continuing to decline.
2 minutes to read